CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
The Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro)-Coated Stent in Acute Myocardial Infarction
Weon Kim, MD*,
Myung Ho Jeong, MD, FACC, FAHA, FESC*,*,
Kye Hun Kim, MD*,
Il Suk Sohn, MD*,
Young Joon Hong, MD*,
Hyung Wook Park, MD*,
Ju Han Kim, MD*,
Young Keun Ahn, MD, FACC*,
Jeong Gwan Cho, MD, FACC*,
Jong Chun Park, MD*,
Dong Lyun Cho, PhD and
Jung Chae Kang, MD*
* Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences
Chemical Engineering of Chonnam National University, Gwangju, Korea
Manuscript received August 31, 2005;
revised manuscript received October 10, 2005,
accepted October 18, 2005.
* Reprint requests and correspondence: Dr. Myung Ho Jeong, Cardiac Catheterization Laboratory, Heart Center of Chonnam National University Hospital, 8 Hak-dong, Dong-gu, Gwangju, 501-757, Korea
(Email: myungho{at}chollian.net).
OBJECTIVES: This study is a prospective randomized trial investigating clinical outcomes of patients with acute myocardial infarction (AMI) treated with abciximab (ReoPro)-coated stents.
BACKGROUND: Recently we have demonstrated that abciximab-coated stents have inhibitory effects in the prevention of coronary restenosis.
METHODS: Ninety-six patients with AMI were randomly allocated into two groups; group I received abciximab-coated stents (n = 48, 57.1 ± 12.0 years), and group II received bare metal control stents (n = 48, 58.4 ± 11.6 years).
RESULTS: At baseline, clinical characteristics, percent diameter stenosis, and minimal luminal diameter were no different between the two groups. One patient in group II had reinfarction and target lesion reintervention during hospital stay. Follow-up coronary angiography was obtained in 77.1% (37 of 48) in group I and 75.0% (36 of 48) in group II. Percent diameter stenosis and late loss were significantly lower in group I than group II (18.9 ± 5.54% vs. 37.9 ± 6.25%, p = 0.008; and 0.39 ± 0.29 mm vs. 0.88 ± 0.45 mm; p = 0.008, respectively). At follow-up intravascular ultrasound, intrastent lumen area and intrastent neointimal hyperplasia (NIH) area were 5.4 ± 1.8 mm2 and 2.2 ± 1.5 mm2, respectively, in group I and 4.3 ± 1.6 mm2 and 3.4 ± 1.8 mm2, respectively, in group II (p = 0.045). And, in-stent restenosis rate was lower in group I than group II (p = 0.011 and p = 0.008, respectively). During 1-year follow-up, two patients in group II (4.1%) had AMI, whereas no patient in group I suffered AMI. Target lesion revascularization and total major adverse cardiac events rates were relatively lower in group I compared with those in group II (10.4% [5 of 48] vs. 20.8% [10 of 48], p = 0.261, and 10.4% vs. 25.0%, p = 0.107, respectively).
CONCLUSIONS: Abciximab-coated stent implantation was safe and effective without stent thrombosis in AMI patients.
This article has been cited by other articles:
|
|
|
|
 
C. S. Rihal
Drug-Eluting Stents for ST-Segment Elevation Myocardial Infarction: Treatment of Choice or Is Discretion the Better Part of Valor?
J. Am. Coll. Cardiol. Intv.,
June 1, 2008;
1(3):
233 - 235.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams
The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention.
J. Am. Coll. Cardiol.,
February 19, 2008;
51(7):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
270 - 285.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Abciximab-Coated Stents in AMI: Saving Muscle . . . or Not
Journal Watch Emergency Medicine,
April 25, 2006;
2006(425):
5 - 5.
[Full Text]
|
|
|
|
